Plain-English translation of NCT06589219 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial tested , a new medication delivered through inhalation (breathing it in like a mist), to see if it was safe and how the body processes it. The study included both healthy volunteers and people with idiopathic pulmonary fibrosis (a condition where lung tissue becomes scarred and stiff over time). Researchers examined whether the medication was well-tolerated and how it affected the lungs and body.
Idiopathic pulmonary fibrosis is a serious condition that gradually makes it harder to breathe as lung tissue scars. This trial was designed to explore whether this new treatment might help slow or manage the disease by delivering the medication directly to the lungs where it's needed most.
Participants in the healthy volunteer groups received the medication (or a placebo) through a nebulizer—a device that turns liquid medicine into a mist you breathe in—either as a single dose or weekly for four weeks, while researchers monitored their safety and how their body processed it. Patients with lung fibrosis received the medication weekly for five weeks through the same nebulizer method. All participants attended visits for blood tests, lung function tests, and medical check-ups to track any effects.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
Germany
Phase
Safety & dosing
Sponsor
Calibr, a division of Scripps Research
Enrollment target
~89 participants
Started
August 2024
Primary completion
June 2026
Age range
18 Years – 60 Years
Last updated on clinicaltrials.gov in July 2026.